

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00474)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of the Company dated 30 March 2025 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as those defined in the Announcement.

As mentioned in the Announcement, the Company will despatch its circular containing, among other things, further details of the JV Agreement and other information as required under the Listing Rules on or before 23 April 2025.

As additional time is required to prepare and finalise certain information to be included in the circular of the Company, the despatch date of the circular will be postponed to a date on or before 9 May 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 23 April 2025

As at the date of this announcement, the Board comprises two executive directors, namely Mr. Fok Chi Tak and Dr. Zhiliang Ou, J. P. (Australia); one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Mak Yiu Tong, Mr. Lam Kwan Sing and Mr. Chan Ming Sun Jonathan.